JCB, Volume 13, Number 3, 2007 Article Vol.13 No. 3 (2007) When should you fire the founder? William Bains This paper examines the effect of founder team removal on the success of a set of 77 UK venture-backed biotechnology companies. Five measurements of success of these (p Article Vol.13 No. 3 (2007) Constructing a processual model of communication in new product development from a multiple case study of biotechnology SMEs Jennifer Frahm For most companies in the biotechnology industry, the core business is new product development (NPD). Indeed, there are still very few companies that have products that Article Vol.13 No. 3 (2007) A maturing industry: Strategic patenting trends, US and academic dominance, and the global biotechnology landscape Gareth Williams Patent analytical data has proved itself a key enabler in measuring the commercial focus and activity taking place within highly research and development (R&D) inte Article Vol.13 No. 3 (2007) Measuring performance of field-medical programmes: Medical science liaison metrics consensus Jane Chin A Medical Science Liaison (MSL) Metrics Consensus initiative aims to identify field-medical activities throughout the pharmaceutical product lifecycle, and metrics asso Article Vol.13 No. 3 (2007) The commercialisation of bioinformatics and the threat of open-source software Joseph F Greco This study investigates the commercialisation process of a select group of bioinformatics companies and the impact of open-source software. Using the research–de Article Vol.13 No. 3 (2007) Intellectual property issues in nanotechnology Lars Genieser Emerging nanotechnologies have the potential to impact a wide range of commercially important bioscience and medical applications. For example, researchers are developi Article Vol.13 No. 3 (2007) Fostering the process of adoption of personalised medicine: A matter of communication or a matter of cost? Pedro Reinares Lara Pharmacogenetics, along with its derived products, diagnostic tests and customised medicines, has been introduced to the market with high commercial expectations (deriv Article Vol.13 No. 3 (2007) Changing hopes and concerns about gene therapy in Japan Darryl Macer The attitudes that the public in Japan have to gene therapy were surveyed through the use of opinion surveys in 1991, 1993, 1995, 2000 and 2003. This paper presents the Legal and Regulatory Updates Vol.13 No. 3 (2007) Legal and regulatory update John Wilkinson  Â
